Saturday, July 11, 2026

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial

Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Clinical program

PRO RCT GRAM 2022

Phase 2 · small molecule · allergic rhinoconjunctivitis caused due to exposure to pollen grasses

PRO RCT GRAM 2022 for allergic rhinoconjunctivitis caused due to exposure to pollen grasses is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

← All Lacuna Pharma Pty Ltd projects Phase 2 small molecule active

Internal code PRO RCT GRAM 2022

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lacuna Pharma Pty Ltd
Phase
Phase 2
Modality
small_molecule
Indication
allergic rhinoconjunctivitis caused due to exposure to pollen grasses
Status
active
Trials
1

Clinical trials